Skip to main
  1. Stocks
  2. Mobia Medical Inc
  3. Forecast
MOBI

MOBI Stock Forecast & Price Target

MOBI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mobia Medical is attractive because it occupies a first-mover, effectively category-defining position in chronic stroke recovery, with Vivistim as the only FDA-approved VNS platform and a large unmet need among roughly 9M ischemic stroke survivors. Clinical feedback and two-year VNS-REHAB data support durable functional gains, while reimbursement friction has eased and the company has already surpassed 1,000 implants since its full commercial launch in 2023, indicating improving adoption. The financial setup also looks compelling, as revenue reached $13.5M in 2Q26 and management has guided FY26 sales to $54M-$56M, while expectations call for about 46% top-line CAGR through FY28 on expanding territories and better payer dynamics.

Bears say

Mobia Medical is vulnerable to downside if Vivistim adoption at new stroke centers is slower than modeled, since all revenue comes from this single product and weaker-than-expected penetration would directly pressure growth. Its outlook also worsens if the broader stroke-recovery market expands more slowly, or if faster average selling price degradation compresses margins and offsets unit growth. In addition, longer product development timelines and higher operating expense spend than modeled could delay operating leverage, increase cash burn, and make the company’s already concentrated business model more fragile.

MOBI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mobia Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

MOBI Analyst Forecast & Price Prediction

Get the latest MOBI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MOBI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mobia Medical Inc (MOBI) Forecast

Analysts have given MOBI a Strong Buy based on their latest research and market trends.

According to 4 analysts, MOBI has a Strong Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mobia Medical Inc (MOBI)


MOBI Analyst Forecast & Price Prediction

Get the latest MOBI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MOBI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MOBI stock data and trends